Table 3 Univariate analysis of the clinical and pathological factors in relation to PFS and OS

Sex

Male

19

2.1(0.8 – 9.1)

10.6(7.0 – 14.3)

1.00

1.00

Female

39

0.3(2.2 – 3.4)

0.5

5.4(3.6 – 7.2)

0.383

1.22

0.7 – 2.2

0.501

1.31

0.7 – 2.4

0.385

Age (ys)

<60

26

2.6(2.1 – 3.1)

5.2(3.4 – 7.1)

1.00

1.00

≥60

32

4.0(1.8 – 6.1)

0.109

9.7(5.5 – 14)

0.303

0.60

0.4 – 1.1

0.112

0.74

0.4 – 1.3

0.305

Smoking

No smoker

14

6.2(0.0 – 12.9)

10.6(3.4 –17.8)

1.00

1.00

Active

44

2.7(2.1 – 3.4)

0.042

5.4(3.6 – 7.2)

0.253

2.00

1.0 – 4.0

0.046

1.5

0.7 – 3.0

0.257

Performance status

0-1

23

2.8(2.2 – 3.5)

6.5(2.6 – 10.4)

1.00

1.00

2-3

5

0.4(0.4 – 0.5)

0.254

0.7(0.1 – 1.4)

0.007

1.77

0.66 – 4.8

0.261

3.88

1.3 – 11.1

0.012

Histology

Adenocarcinoma

46

2.8(1.9 – 3.6)

7.7(3.8 – 11.6)

1.00

1.00

Squamous

6

2.7(1.5 – 3.9)

0.267

4.4(2.5 – 6.2)

0.045

1.65

0.68 – 4.0

0.273

2.47

0.99 – 6.2

0.054

Stage

I-III

19

2.8(2.2 – 3.5)

10.0(5.4 – 14.6)

1.00

1.00

IV

39

3.3(2.0 – 4.6)

0.545

5.8(2.9 – 8.8)

0.315

1.20

0.66 – 2.2

0.546

1.37

0.7 – 2.5

0.318

Prior treatment

No

12

3.1(1.7 – 4.6)

5.0(2.4 – 7.7)

1.00

1.00

Yes

46

2.8(2.0 – 3.7)

0.650

7.4(3.5 – 11.3)

0.386

0.86

0.5 – 1.6

0.651

0.74

0.4 – 1.5

0.389

Toxicity

No

7

1.8(1.6 – 2.1)

2.3(1.8 – 2.8)

1.00

1.00

Yes

49

3.8(2.2 – 5.3)

<0.001

7.8(4.1 – 11.5)

0.009

0.44

0.21 – 0.93

0.031

0.35

0.15 – 0.8

0.013